2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
10
Uveal Melanoma
3
Multiple Myeloma
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Eye Neoplasms
1
Interventions
Ifosfamide
30
Methotrexate
29
Doxorubicin
26
Cyclophosphamide
24
Cisplatin
22
Filgrastim
18
Etoposide
17
Gemcitabine
16
Leucovorin
14
Magnetic Resonance Spectroscopy
11
Temozolomide
10
Specimen Handling
10
cabozantinib
9
apatinib
9
X-Rays
9
Carboplatin
9
fludarabine
8
Radiotherapy
8
Nivolumab
8
Neoadjuvant Therapy
8
Irinotecan
8
Granulocyte Colony-Stimulating Factor
8
Drug Therapy
8
Docetaxel
8
Zoledronic Acid
7
Vincristine
7
Sirolimus
7
Phantoms, Imaging
7
Biopsy
7
mifamurtide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
MAGEA3 protein, human
×
Clear all
NCT00944580
2017-11-24
A Vaccine Study for High Risk Cancers
Penn State University
Phase 1
Withdrawn